TEM Stock Declines Following Preliminary Q4 Sales Miss

Tempus AI, Inc. (TEM) , a leader in precision medicine and AI-enabled diagnostics, announced preliminary financial results for the fourth quarter and fiscal 2024. The company also provided additional details at the 43rd Annual J.P. Morgan Healthcare Conference, including forward-looking plans for 2025, emphasizing growth across genomics, data services and applications. The company's shares fell 13.8% on Jan. 13 as the top line missed market expectations.Tempus plans to report its complete fourth-quarter and ...